Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 86Bevacizumab 66Capecitabine 65Fluorouracil 48tislelizumab 41Gemcitabine 40Drug Therapy 39Leucovorin 38sintilimab 35Irinotecan 34lenvatinib 27Cisplatin 27HMPL-013 25S 1 (combination) 23camrelizumab 22Immune Checkpoint Inhibitors 21irinotecan sucrosofate 20apatinib 20Surgical Procedures, Operative 20Radiotherapy 20Injections 20130-nm albumin-bound paclitaxel 20toripalimab 19Paclitaxel 18Folfox protocol 17pembrolizumab 15Immunotherapy 15Cetuximab 15Specimen Handling 14regorafenib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × pirfenidone × Gastrointestinal × Clear all
NCT07268677 2025-12-08

A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.

Fudan University

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06484153 2024-07-03

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1/2 Not yet recruiting
25 enrolled
Gastrointestinal

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡